Overview

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Status:
Completed

Trial end date:
2017-08-15

Target enrollment:

Participant gender:

Summary

This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences
Sierra Oncology, Inc.

Treatments:

N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide